Roche's oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with
People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable therapies developed by ViiV Healthcare and
After turning down routine NHS funding of Bristol-Myers Squibb's Inrebic for bone marrow disorder myelofibrosis earlier this year, NICE now says the drug can be made available via the Cance
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm
NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin's Poteligeo for two rare blood cancers, ending the threat of a north-south divide in access to the drug in the
